Payment overview · 2025
General Payments
$1,445.02
87 reported records · 20 companies
Healthcare provider profile · identity verified
Stephen C Hammack, MD
Allopathic & Osteopathic Physicians|Family Medicine · FLOWOOD, MS · NPI 1639396393
Verified facts
What the public records show
CMS Open Payments records show Stephen C Hammack, MD received $1,445.02 in general payments during 2025 across 87 reported records.
ABBVIE INC. accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Mounjaro, Ozempic, Shingrix, Synthroid, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $323.29 | 22.4% | 22 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $236.74 | 16.4% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $223.44 | 15.5% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $207.26 | 14.3% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $78.24 | 5.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $66.33 | 4.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $60.10 | 4.2% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.58 | 2.1% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.33 | 1.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.14 | 1.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.39 | 1.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.07 | 1.4% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $18.89 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.79 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.06 | 1.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.66 | 1.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.62 | 1.2% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.33 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.91 | 1.0% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $13.85 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,445.02 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $215.24 | 14 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $198.07 | 13 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $179.39 | 11 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $147.02 | 6 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $147.02 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $147.02 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $128.29 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $128.29 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $112.61 | 9 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $78.24 | 5 | 2025 |
Source payment records
|
|||||
| BOOSTRIX Normalized: boostrix |
Biological | GlaxoSmithKline, LLC. | $78.24 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $78.24 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $76.42 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $76.42 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $66.33 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $66.33 | 3 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $41.29 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.58 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.38 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $30.58 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.50 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 69 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 33 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
33 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 208 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 152 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 132 | 20 |
| Meloxicam | Meloxicam | 123 | 30 |
| Gabapentin | Gabapentin | 120 | 32 |
| Furosemide | Furosemide | 100 | 30 |
| Allopurinol | Allopurinol | 89 | 18 |
| Metformin Hcl | Metformin Hcl | 88 | 25 |
| Lisinopril | Lisinopril | 82 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 25 |
| Mounjaro | Tirzepatide | 69 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 67 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 18 |
| Cefuroxime | Cefuroxime Axetil | 64 | 55 |
| Potassium Chloride | Potassium Chloride | 63 | 17 |
| Jardiance | Empagliflozin | 62 | suppressed |
| Alprazolam | Alprazolam | 61 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 19 |
| Omeprazole | Omeprazole | 61 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 58 | 13 |
| Eliquis | Apixaban | 57 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 56 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 12 |
| Losartan Potassium | Losartan Potassium | 49 | 18 |
| Ozempic | Semaglutide | 48 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 48 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 48 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 47 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Clonazepam | Clonazepam | 40 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 12 |
| Valsartan | Valsartan | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 33 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 32 | 13 |
| Carvedilol | Carvedilol | 31 | 11 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Colchicine | Colchicine | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 12 |
| Montelukast Sodium | Montelukast Sodium | 28 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Famotidine | Famotidine | 26 | 12 |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Prednisone | Prednisone | 20 | 17 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Mupirocin | Mupirocin | 18 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,445.02 · 87 records | ABBVIE INC. | ABRYSVO, AREXVY, AUSTEDO XR, Azstarys, BOOSTRIX, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, CT THROMBECTOMY SYSTEM KIT, ELIQUIS, FLOWTRIEVER CATHETER, S, FREESTYLE LIBRE 3, GARDASIL 9, GIVLAARI, INSPIRE, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, OFEV, OTEZLA, Ozempic, PREVNAR 20, PROCLAIM, QULIPTA, Qelbree, REPATHA, Rybelsus, SHINGRIX, SYNTHROID, Saxenda, The Cologuard Plus Collection Kit, UBRELVY, VAXELIS, VOQUEZNA, VRAYLAR, WaveWriter Alpha Prime 16, Wegovy, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error